Innovations for Next-Generation Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the i...

Full description

Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Damelin, Marc (Editor, http://id.loc.gov/vocabulary/relators/edt)
Format: Electronic eBook
Language:English
Published: Cham : Springer International Publishing : Imprint: Humana, 2018.
Edition:1st ed. 2018.
Series:Cancer Drug Discovery and Development,
Subjects:
Online Access:Full Text via HEAL-Link
Table of Contents:
  • Chapter 1 Introduction: Motivations for Next-Generation ADCs
  • Chapter 2 Combining ADCs with Immuno-oncology Agents
  • Chapter 3 Improving the Safety Profile of ADCs
  • Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development
  • Chapter 5 Regulatory Considerations and Companion Diagnostics
  • Chapter 6 ADC Process Development and Manufacturing
  • Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development
  • Chapter 8 Next generation payloads for ADCs
  • Chapter 9 Delivering more payload: High DAR ADCs
  • Chapter 10 Site-Specific Antibody Drug Conjugates
  • Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates
  • Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates
  • Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment
  • Chapter 14 Next Horizons: ADCs Beyond Oncology.